PF-07868489
Protein / enzyme therapeutic
Evidence outlook · program status
Discontinued (2026-10), as a strategic decision by the sponsor
No active registered trials remain; latest study NCT07073820 (Phase 2) was terminated with whyStopped: "The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.". The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06137742 NCT06137742 · Pulmonary Arterial Hypertension The patient-facing portion of this trial (Part B) randomized people with pulmonary arterial hypertension to PF-07868489 or placebo under double-blind conditions for 24 weeks, measuring change in pulmonary vascular resistance, a direct hemodynamic measure of disease severity, by right heart catheterization. The design is well controlled, but results have not yet been posted, so whether the drug improved this measure is not known. Registry: NCT06137742 | 1/2 | Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to Day 113.); Number of Participants With Change From Baseline in Laboratory Tests Results (Baseline up to Day 113); Number of Participants With Vital Sign Abnormalities (Baseline up to Day 113); Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters (Baseline up to Day 113); Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to Day 253); Number of Participants With Change From Baseline in Laboratory Tests Results (Baseline up to Day 253); Number of Participants With Vital Sign Abnormalities (Baseline up to Day 253); Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters (Baseline up to Day 253); Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24 (Baseline, Week 24) 2026-07-31 | Results not posted; external-source review pending | Partial signal | link ↗ |
View 1 more trial
NCT07073820 NCT07073820 · Pulmonary Arterial Hypertension Registry: NCT07073820 | 2 | Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to week 111); Number of Participants With Change From Baseline in Laboratory Tests Results (Baseline up to week 111); Number of Participants With Vital Sign Abnormalities (Baseline up to week 111) 2026-10-09 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Pulmonary Arterial Hypertension: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PF-07868489: this drug | Discontinued | Protein / enzyme therapeutic | Bone morphogenetic protein 9 (BMP9) | not yet graded | No reviewed efficacy summary in this indication | |
| Ambrisentan (Letairis) | Approved | Small molecule | Endothelin A receptor | Reliable signal | NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001). | |
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant) NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults. | |
| Epoprostenol (Flolan) | ApprovedUS marketing discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Macitentan (Opsumit) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier | |
| Riociguat (Adempas) | Approved | Small molecule | Soluble guanylate cyclase | Reliable signal | NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5) | |
| Sildenafil (Revatio) | Approved | Small molecule | PDE5 | Partial signal | NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). | |
| Sotatercept (Winrevair) | Approved | Protein / enzyme therapeutic | Activin receptor type IIA (ActRIIA) | Reliable signal | NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025). | |
| Tadalafil (Adcirca) | Approved | Small molecule | PDE5 | Weak signal | NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks. | |
| Treprostinil (Orenitram) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) | |
| Treprostinil (Remodulin) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | Featured results are safety only in this race | |
| Extended-Release Tacrolimus (VI-0106) | Phase 3 | Small molecule | Calcineurin | not yet graded | No reviewed efficacy summary in this indication | |
| Imatinib Mesylate Prodrug (IkT-001Pro) | Phase 3 | Small molecule | PDGFR (imatinib-class) | not yet graded | No reviewed efficacy summary in this indication | |
| Ralinepag | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. | |
| Seralutinib | Phase 3 | Small molecule | PDGFR/CSF1R/KIT (multi-kinase) | Partial signal | NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Udenafil (Zydena) | Phase 2/3 | Small molecule | PDE5 | Weak signal | No reviewed efficacy summary in this indication | |
| APL-9796 | Phase 2 | Monoclonal antibody | ZIP12 (zinc transporter) | not yet graded | No reviewed efficacy summary in this indication | |
| ROC-101 | Phase 2 | Small molecule | Rho-associated kinase (ROCK, pan) | not yet graded | No reviewed efficacy summary in this indication | |
| Vasigrobart | Phase 2 | Monoclonal antibody | PDGF-B | not yet graded | No reviewed efficacy summary in this indication | |
| Zamicastat | Phase 2 | Small molecule | DBH | Weak signal | No reviewed efficacy summary in this indication | |
| HS235 | Phase 1/2 | Peptide | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| F230 | —(overall) | Small molecule | Endothelin A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| GSK6792070 | —(overall) | Undisclosed | Activin signalling | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1) |
Upcoming events
No upcoming readouts on record for this asset.